Evotec : Company Presentation 2.985 MB

General company presentation

Evotec SE, Company presentation, May 2024

Disclaimer

This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the "Company", "we," "our" or "us"). This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy Evotec securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No representations or warranties, express or implied, are made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and neither the Company nor any of its directors, officers, employees, affiliates, agents, advisors or representatives shall have any liability relating thereto.

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this presentation can be identified by the use of forward- looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward- looking statements due to a variety of factors. The forward-looking statements contained in this presentation speak only as of the date of this presentation, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.

PAGE 2

1. Together for Medicines that Matter
2. Shared R&D
3. Just - Evotec Biologics
4. Financials

PAGE 3

The core idea of Evotec - evolutionary technology

"The goal of Evolution is not

one single human, it is mankind."

Eigen's theories about self-organisation of complex molecules and his development of the evolution machine founded a new branch of science - evolutionary biotechnology.

Manfred Eigen (1927-2019)

Co-founder of Evotec, Nobel Prize 1967

PAGE 4

Evotec was founded 1993

Accelerating medicines that matter

About us

4,000++ scientists		Co-creating pipelines
empowering our partners		Leveraging our assets, targets or proprietary platforms for licensing,
Across all disciplines and disease areas from		co-development or potential NewCo creation, frequently combining
target to commercial manufacturing		with Partners' programs, and ideas

R&D Biotech that offers accelerated, high-value pipeline co-creation, and R&D solutions

Performance - "Beyond FTEs"

Collaborating with "end in mind", result-driven partnership models

Track record - highest quality, most capital-efficient execution

State-of-the-art services as core offering for partners

PAGE 5

Scientific AND operational excellence are both essential for our success

Benefits of increased emphasis on Operational excellence

Shared R&D - From target to patient

Discovery of next generation drugs with higher efficacy and probability of success through industrialised PanOmics approach towards molecular disease understanding and E.iPSC disease modeling platform.

In-vitro & in-silico prediction of human exposure, clinical efficacy and toxicological outcome of a drug or chemical.

Design and execution of best strategy for rapid entry into crucial first in human studies and further advancement into clinical supply.

Just - Evotec Biologics - Global access to biotherapeutics

Design and application of innovative technologies from discovery to commercial supply to dramatically expand global access to biotherapeutics.

Integrated continuous manufacturing platforms operating within cGMP facilities that employ autonomous clean room technology for the cost-efficient production of antibodies, next- generation biologics and biosimilar products.

PAGE 6

A shared economy model in R&D as basis for success

A stable foundation

		RoW
>500	~47%	12%
Revenue
Active partners	Revenue share with	Europe 28% by region 60%	USA
	TOP 10 partners

			NFP, Academic,
			Foundations
>93%	102	Top 20	12%
by partner 35% Biotech
		Pharma
		37%	Revenue
Repeat	No. of partners with
business	> € 1 m revenues		%
			15
		Large Biotech /
		Mid-sized Pharma

PAGE 7

Sustainable growth enabled by commitment, culture, values & people

Selected ESG-KPIs

		75%					33%	32%
			25%
				Evotec SE	Share of PhDs	Women in Leadership
		Peers without ´		Peers with
		SBTi targets		SBTi targets
		EcoVadis Score			93	46%
			52%			Men
		39%
				Evotec: 60		~5,000x
					talent
							Nationalities
					0%		54%
		4%		5%
								Women
		0-2525-45	45-6565-8585-100

PAGE 8

Derived from company information from: Charles River, Catalent, Wuxi Apptech, Wuxi Bio, Sartorius, Lonza, Qiagen, Eurofins, Danaher, Abcellera, Fate Therapeutics, Sana Biotechnology, Schrodinger, Recursion, Exscientia

The growing "iceberg" of first & best-in-class treatment options

>140 co-owned projects

Inflammation &

Neuroscience & pain

Oncology

Metabolic diseases

Immunology1

Virology, Anti-bacterial & Global health

Approved

Jingxin

SK Bio

PhIII

PhII

Carrick

Carrick

Carrick

Carrick

Sernova

Topas

Clinical

Centrexion

Bayer

Topas

PhI

BMS

Kazia

Exscientia

Immunitas

Conba

Exscientia

NIH

ND

ND

ND

ND

EVT

EVT

ND

EVT

EVT

ND

ND

ND

ND

EVT

EVT

ND

EVT

EVT

ND

ND

ND

ND

EVT

EVT

ND

EVT

EVT

EVT

ND

ND

ND

ND

ND

EVT

ND

EVT

EVT

EVT

EVT

EVT

ND

ND

ND

ND

ND

EVT

ND

EVT

EVT

EVT

EVT

EVT

Pre-clinical &

ND

ND

ND

ND

ND

EVT

EVT

ND

EVT

EVT

EVT

EVT

EVT

Discovery

ND

ND

ND

ND

ND

EVT

EVT

ND

EVT

EVT

EVT

ND

EVT

EVT

ND

ND

ND

EVT

ND

ND

ND

EVT

EVT

ND

ND

EVT

EVT

ND

ND

ND

EVT

EVT

ND

ND

ND

EVT

ND

ND

ND

EVT

EVT

ND

ND

EVT

EVT

ND

EVT

ND

ND

ND

EVT

EVT

ND

ND

ND

EVT

ND

ND

ND

EVT

EVT

ND

ND

EVT

EVT

ND

EVT

ND

ND

ND

EVT

EVT

>50

>120

	Partnered Pipeline		Unpartnered Pipeline		Equity Pipeline		Bridges Pipeline

PAGE 9	1 Also includes Women's Health, Respiratory projects
	The Equity Pipeline does not contain programs from EVT/partners that are not publicly disclosed
	Status as of 31 December 2023

Shared R&D - Discovery of next generation drugs with higher efficacy and probability of success

PAGE 10